Please assess the completion status of the following clinical trial:

Trial Title: Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 10 years of age or older~2. Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 36 months or less before randomization:~   1. An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)~  2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest refraction~  3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction~  4. Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.~3. Subjects with keratoconus diagnosis only:~   a. Axial topography consistent with keratoconus b. Presence of central or inferior steepening on the Pentacam map. c. Presence of one or more slit lamp findings associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal thinning iv. Corneal scarring~4. Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:~   Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks~5. Signed written informed consent~Exclusion Criteria:~* 1. Any keratoconus patient over 21 years of age without evidence of progression of his corneal deformity.~  2. Patients with excessively thin corneas. 3. Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:~  a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. Clinically significant corneal scarring in the proposed treatment zone 4. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.~  5. A known sensitivity to treatment medications. 6. Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.~  7. Pregnancy (including plan to become pregnant) or lactation during the course of the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riboflavin 0.1% eyedrops every 5 minutes (Type: ACTIVE_COMPARATOR): The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
- Riboflavin 0.1% eyedrops every 2 minutes (Type: ACTIVE_COMPARATOR): The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).